Discrimination of HLA null and low expression alleles by cytokine-induced secretion of recombinant soluble HLA

Molecular Immunology

Volumn 46, Issue 7, 2009, Pages 1451-1457

  Hinrichs, Jan ^a   Figueiredo, Constança ^a   Hirv, Kaimo ^b   Mytilineos, Joannis ^b   Blasczyk, Rainer ^a   Horn, Peter A ^a,c   Eiz Vesper, Britta ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

HLA expression; HLA A*3014L; Null alleles; Stem cell transplantation

Indexed keywords

BETA 2 MICROGLOBULIN; CYSTEINE; CYTOKINE; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN; MESSENGER RNA; RECOMBINANT ANTIGEN; SERINE; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CELL STRAIN K 562; CONTROLLED STUDY; DISULFIDE BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; GENE EXPRESSION; GENETIC TRANSFECTION; HLA SYSTEM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; STRESS; SUPERNATANT;

ALLELES; CELLS, CULTURED; CLONING, MOLECULAR; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY TESTING; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; K562 CELLS; MUTATION; RECOMBINANT PROTEINS; SECRETORY PATHWAY; SOLUBILITY; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EUKARYOTA;

EID: 62749097890     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.12.011     Document Type: Article

References (31)

1. Bade-Doeding C., Elsner H.A., Eiz-Vesper B., Seltsam A., Holtkamp U., and Blasczyk R. A single amino-acid polymorphism in pocket A of HLA-A*6602 alters the auxiliary anchors compared with HLA-A*6601 ligands. Immunogenetics 56 (2004) 83-88
2. Bade-Doeding C., DeLuca D.S., Seltsam A., Blasczyk R., and Eiz-Vesper B. Amino acid 95 causes strong alteration of peptide position Pomega in HLA-B*41 variants. Immunogenetics 59 (2007) 253-259
3. Balas A., Garcia-Sanchez F., Gomez-Reino F., and Vicario J.L. HLA class I allele (HLA-A2) expression defect associated with a mutation in its enhancer B inverted CAT box in two families. Hum. Immunol. 41 (1994) 69-73
4. Dunn P.P., Turton J.R., Downing J., Williams S., Navarrete C.V., and Darke C. HLA-A*24020102L in the UK blood donor population. Tissue Antigens 63 (2004) 589-591
5. Elsner H.A., and Blasczyk R. Immunogenetics of HLA null alleles: implications for blood stem cell transplantation. Tissue Antigens 64 (2004) 687-695
6. Elsner H.A., Horn P.A., Schoenemann C., Altermann W.W., and Blasczyk R. Aberrant expression of HLA-B*3565Q is associated with a disrupted disulfide bond. Immunogenetics 58 (2006) 929-931
7. Früh K., and Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr. Opin. Immunol. 11 (1999) 76-81
8. Girdlestone J. Transcriptional regulation of MHC class I genes. Eur. J. Immunogenet. 23 (1996) 395-413
9. Gobin S.J., Peijnenburg A., Keijsers V., and van den Elsen P.J. Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 6 (1997) 601-611
10. Gobin S.J., Keijsers V., van Zutphen M., and van den Elsen P.J. The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J. Immunol. 161 (1998) 2276-2283
11. Gobin S.J., van Zutphen M., Woltman A.M., and van den Elsen P.J. Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J. Immunol. 163 (1999) 1428-1434
12. Henry J.B., Hubbell C.A., Davis M.C., Fernandez-Vina M.A., Yunis E.J., and Shrimpton A.E. A new HLA-A1 mutation: a novel, null variant allele. Am. J. Clin. Pathol. 122 (2004) 185-192
13. Hirv K., Pannicke U., Mytilineos J., and Schwarz K. Disulfide bridge disruption in the alpha2 domain of the HLA class I molecule leads to low expression of the corresponding antigen. Hum. Immunol. 67 (2006) 589-596
14. Johnson D.R. Locus-specific constitutive and cytokine-induced HLA class I gene expression. J. Immunol. 170 (2003) 1894-1902
15. Johnson D.R., and Pober J.S. Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy- and light-chain genes in vascular endothelium. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 5183-5187
16. Krausa P., Munz C., Keilholz W., Stevanovic S., Jones E.Y., Browning M., Bunce M., Rammensee H.G., and McMichael A. Definition of peptide binding motifs amongst the HLA-A*30 allelic group. Tissue Antigens 56 (2000) 10-18
17. Laforet M., Froelich N., Parissiadis A., Bausinger H., Pfeiffer B., and Tongio M.M. An intronic mutation responsible for a low level of expression of an HLA-A*24 allele. Tissue Antigens 50 (1997) 340-346
18. Lankat-Buttgereit B., and Tampe R. The transporter associated with antigen processing: function and implications in human diseases. Physiol. Rev. 82 (2002) 187-204
19. Ma W., Lehner P.J., Cresswell P., Pober J.S., and Johnson D.R. Interferon-gamma rapidly increases peptide transporter (TAP) subunit expression and peptide transport capacity in endothelial cells. J. Biol. Chem. 272 (1997) 16585-16590
20. Magor K.E., Taylor E.J., Shen S.Y., Martinez-Naves E., Valiante N.M., Wells R.S., Gumperz J.E., Adams E.J., Little A.M., Williams F., Middleton D., Gao X., McCluskey J., Parham P., and Lienert-Weidenbach K. Natural inactivation of a common HLA allele (A*2402) has occurred on at least three separate occasions. J. Immunol. 158 (1997) 5242-5250
21. Miyazaki J., Appella E., and Ozato K. Intracellular transport blockade caused by disruption of the disulfide bridge in the third external domain of major histocompatibility complex class I antigen. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 757-761
22. Natarajan K., Li H., Mariuzza R.A., and Margulies D.H. MHC class I molecules, structure and function. Rev. Immunogenet. 1 (1999) 32-46
23. Oudshoorn M., Horn P.A., Tilanus M., and Yu N. Typing of potential and selected donors for transplant: methodology and resolution. Tissue Antigens 69 Suppl. 1 (2007) 10-12
24. Perrier P., Dormoy A., Andre-Botte C., and Froelich N. HLA-A*02010102L: a laborious assignment. Tissue Antigens 68 (2006) 442-445
25. Robinson J., and Marsh S.G. HLA informatics. Accessing HLA sequences from sequence databases. Methods Mol. Biol. 210 (2003) 3-21
26. Saper M.A., Bjorkman P.J., and Wiley D.C. Refined structure of the human histocompatibility antigen HLA-A2 at 2, 6 Å resolution. J. Mol. Biol. 219 (1991) 277-319
27. Solheim J.C. Class I MHC molecules: assembly and antigen presentation. Immunol. Rev. 172 (1999) 11-19
28. van Rood J.J., and Oudshoorn M. Eleven million donors in Bone Marrow Donors Worldwide! Time for reassessment?. Bone Marrow Transplant. 41 (2008) 1-9
29. Warburton R.J., Matsui M., Rowland-Jones S.L., Gammon M.C., Katzenstein G.E., Wei T., Edidin M., Zweerink H.J., McMichael A.J., and Frelinger J.A. Mutation of the alpha 2 domain disulfide bridge of the class I molecule HLA-A*0201. Effect on maturation and peptide presentation. Hum. Immunol. 39 (1994) 261-271
30. Zeff R.A., Gopas J., Steinhauer E., Rajan T.V., and Nathenson S.G. Analysis of somatic cell H-2 variants to define the structural requirements for class I antigen expression. J. Immunol. 137 (1986) 897-903
31. Zeff R.A., Nakagawa M., Mashimo H., Gopas J., and Nathenson S.G. Failure of cell surface expression of a class I major histocompatibility antigen caused by somatic point mutation. Transplantation 49 (1990) 803-808